Relapsing Multiple Sclerosis

Neurology·MeSH: Multiple Sclerosis

Prevalence

120.0 / 100K

Incidence

7.0 / 100K/yr

32 drugs in development·7 companies·19 clinical trials

Drug Pipeline by Phase

Phase 3(25)

Drug	Company
13-valent pneumococcal conjugate vaccine	Novartis AG (NVS)
13-valent pneumococcal conjugate vaccine	NOVARTIS AG (NVSEF)
23-valent pneumococcal polysaccharide vaccine	NOVARTIS AG (NVSEF)
23-valent pneumococcal polysaccharide vaccine	Novartis AG (NVS)
keyhole limpet hemocyanin neo-antigen	Novartis AG (NVS)
keyhole limpet hemocyanin neo-antigen	NOVARTIS AG (NVSEF)
obexelimab	Zenas BioPharma, Inc. (ZBIO)
ocrelizumab	Novartis AG (NVS)
ofatumumab	Novartis AG (NVS)
ofatumumab approved dose	Novartis AG (NVS)
Ofatumumab approved dose	Novartis AG (NVS)
ofatumumab new dose	Novartis AG (NVS)
Ofatumumab new dose	Novartis AG (NVS)
ozanimod	CELGENE CORP /DE/ (CELG)
Remibrutinib	Novartis AG (NVS)
remibrutinib oral treatment	Novartis AG (NVS)
Remibrutinib oral treatment	Novartis AG (NVS)
seasonal quadrivalent influenza vaccine	Novartis AG (NVS)
seasonal quadrivalent influenza vaccine	NOVARTIS AG (NVSEF)
teriflunomide hmr1726	Sanofi (SNY)
tetanus toxoid containing vaccine (td	NOVARTIS AG (NVSEF)
tetanus toxoid containing vaccine (td	Novartis AG (NVS)
Ublituximab	TG THERAPEUTICS, INC. (TGTX)
Ublituximab IV Simplified Dosing Schedule	TG THERAPEUTICS, INC. (TGTX)
Ublituximab Subcutaneous	TG THERAPEUTICS, INC. (TGTX)

Phase 2(2)

Drug	Company
sar442168	Sanofi (SNY)
Tolebrutinib	Sanofi (SNY)

Phase 2/Phase 3(2)

Drug	Company
CABA-201	Cabaletta Bio, Inc. (CABA)
Fingolimod	TG THERAPEUTICS, INC. (TGTX)

Phase 4(3)

BioSniper tracks 32 drugs in development for Relapsing Multiple Sclerosis across 7 companies.

There are 19 clinical trials targeting Relapsing Multiple Sclerosis tracked by BioSniper.

The estimated prevalence of Relapsing Multiple Sclerosis is approximately 120.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.